Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
LUF7445/A2A antagonist (AC136)
Cat.#: ASSD-136
Specifications
Description A2A antagonist. Binds irreversibly. Apparent pKi values at A2ARs are 8.27 (after 0.5h) and 8.99 (after 3h), where a Ki shift indicates a covalent mode of action. Size 50 μg Chemical Name 4-[3-[[7-Amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl]amino]propylcarbamoyl]benzenesulfonyl fluoride Molecular formula C18H17FN8O4S PubChem identifier 145958874 Purity >95% Solubility Soluble in DMSO Storage Store at -20° C Shipping Shipped at 4°C Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Size Price ASSD-201 Fluoresceinamine Hydrochloride Isomer 1 (AC201) 2 g inquiry ASSD-121 Fluorescent adenosine A3 antagonist [XAC] (AC121) 500 μg inquiry ASSD-135 JC-1 (AC135) 5 mg inquiry ASSD-214 8-Aminopyrene-1,3,6-trisulfonic acid trisodium salt (AC214) 10 mg inquiry ASSD-215 1-Pyrenylmethyl Methanethiosulfonate (AC215) 10 mg inquiry ASSD-191 Fluorescein 6-Isothiocyanate, Isomer 2, 95% (AC191) 100 mg inquiry ASSD-199 4,7-Dioxaoctylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[2-fluoro-4′-phosphophenylacetic Acid] Diamide (AC199) 500 μg inquiry ASSD-154 Brilliant Blue R-250 (AC154) 1g, 5g inquiry ASSD-186 Bromocresol Purple (AC186) 5 g, 10 g inquiry ASSD-224 Antifade Fluorescence Mounting Medium with DAPI (aqueous) (AC224) 10 mL inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket